Martin Deterre

About Martin Deterre

Martin Deterre is the Chief Executive Officer of Theraclion, the French medtech company listed on Euronext Growth Paris and focused on non-invasive robotic echotherapy solutions. He was appointed CEO by the board on May 24, 2023, after serving as Theraclion’s Director of Engineering and Development since 2020. Theraclion states that he successfully led the development of new generations of SONOVEIN®, and that he has shown an ability to deliver ambitious goals quickly, with a pragmatic and execution-driven style. His mandate is closely tied to Theraclion’s growth strategy, which is built around three main priorities: access to the U.S. market through a pivotal FDA study, expansion in China through the long-term partnership with Furui, and continued product innovation in artificial intelligence, robotics, and treatment protocol improvement. Under his leadership, Theraclion has highlighted strategic milestones including the acceleration of treatment volumes, the strengthening of its commercialization model, and meaningful technological and regulatory progress. In 2025 and early 2026, the company reported a decisive year in which clinical, industrial, and commercial foundations were reinforced, alongside new contracts and the scaling of its Pay-Per-Use model. Before becoming CEO, Martin Deterre built his reputation as a technical executive at the core of Theraclion’s product development efforts, working on the Sonovein® and Echopulse® platforms in a business where clinical innovation, regulatory compliance, and international expansion are essential. His role now is to convert Theraclion’s technological leadership into sustainable commercial performance while maintaining financial discipline and careful capital allocation. This blend of engineering expertise, industrial execution, and strategic leadership makes him a key figure in Theraclion’s current trajectory.